REGENXBIO Inc.
RGNX
$6.72
$0.172.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -7.66% | -15.14% | -8.18% | -20.90% | -19.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.66% | -15.14% | -8.18% | -20.90% | -19.94% |
| Cost of Revenue | 38.37% | -110.80% | -108.89% | -106.96% | -105.79% |
| Gross Profit | -12.58% | 187.42% | 182.70% | 157.19% | 158.31% |
| SG&A Expenses | -18.42% | -17.30% | -11.14% | -2.51% | 2.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 117.88% | 101.03% | 102.28% | 102.32% | 102.80% |
| Total Operating Expenses | -11.31% | -8.33% | -7.14% | -5.99% | -3.65% |
| Operating Income | 12.55% | 5.66% | 6.76% | -0.32% | -3.54% |
| Income Before Tax | 13.86% | 8.30% | 12.02% | 3.71% | 5.98% |
| Income Tax Expenses | -- | -253.49% | -253.49% | -253.49% | -80.95% |
| Earnings from Continuing Operations | 13.81% | 8.34% | 12.07% | 3.75% | 6.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.81% | 8.34% | 12.07% | 3.75% | 6.00% |
| EBIT | 12.55% | 5.66% | 6.76% | -0.32% | -3.54% |
| EBITDA | 12.98% | 5.83% | 7.48% | 0.82% | -1.91% |
| EPS Basic | 23.49% | 15.84% | 16.62% | 5.90% | 7.24% |
| Normalized Basic EPS | 23.22% | 15.52% | 16.34% | 8.53% | 5.99% |
| EPS Diluted | 23.53% | 15.94% | 16.65% | 5.85% | 7.20% |
| Normalized Diluted EPS | 23.22% | 15.52% | 16.34% | 8.53% | 5.99% |
| Average Basic Shares Outstanding | 13.19% | 9.71% | 6.20% | 2.37% | 1.35% |
| Average Diluted Shares Outstanding | 13.19% | 9.71% | 6.20% | 2.37% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
